

# CERTIFICATE

Survey of 03 June 2020

You have fulfilled the requirements of the External Quality Assessment with the following analysis

## Haemostasis 13 - LMW Heparin (281):

Validity 12 months:

Low mol. weight Heparin

## Haemostasis 22 - Dabigatran (502):

Validity 12 months:

Dabigatran

## Haemostasis 23 - Rivaroxaban (503):

Validity 12 months:

Rivaroxaban

## Haemostasis 25 - Apixaban (504):

Validity 12 months:

Apixaban

(R) analysis is subject to the RiliBÄK

### Participant:

2430

MUDr., PhD. Martin Spacek


Vseobecná fakultní nemocnice v Praze

Centrální hematologické laboratorie ULBLD


U Nemocnice 2

12808 Praha 2

Düsseldorf, 07 July 2020



Prof. Dr. med. Michael Spannagl  
(Head of Reference Institution)



Prof. Dr. med. Dirk Peetz  
(Adviser)